Cardioprotective effect of estrogen and raloxifene

雌激素和雷洛昔芬的心脏保护作用

基本信息

项目摘要

Recent evidence suggests that the direct actions of estrogen on blood vessels contribute to the cardioprotective effects of estrogen. There are many kinds of direct effects of estrogen on blood vessels, such as estrogen-induced increases of vasodilatation and inhibition of the response of blood vessels to injury and the development of atherosclerosis.Although both estrogen and raloxifene activate NO synthesis in endothelial cells, the mechanism of inhibition of the response of blood vessels to injury by estrogen and raloxifene remains unclear. We identified that both estrogen and raloxifene decrease the apoptosis and act as a survival factor. Since blockage of Akt-BAD cascade by gene transfection and addition of inhibitor attenuated the decrement of apoptosis by estrogen and raloxifene, Akt-BAD cascade is involved in the inhibition of the response of blood vessels to injury by estrogen and raloxifene. Moreover, we identified that estrogen and raloxifene act as a survival factor thorough ERα, but not ERα Lastly, we examined the effect of surgical menopause on the function of vascular endothelium by brachial artery flow mediated dilatation. The function of vascular endothelium was significantly decreased after 1 week of surgical menopause.
最近的证据表明,雌激素对血管的直接作用有助于雌激素的心脏保护作用。雌激素对血管的直接作用有多种,如增强血管舒张功能,抑制血管对损伤的反应和动脉粥样硬化的发展,虽然雌激素和雷洛昔芬都能激活内皮细胞合成NO,但雌激素和雷洛昔芬抑制血管对损伤反应的机制尚不清楚。我们发现雌激素和雷洛昔芬都能减少细胞凋亡,并作为一种生存因子。由于通过基因转染和添加抑制剂阻断Akt-BAD级联反应减弱了雌激素和雷洛昔芬对细胞凋亡的减少,因此Akt-BAD级联反应参与了雌激素和雷洛昔芬对血管损伤反应的抑制。雌激素和雷洛昔芬通过ERα而不是ERα发挥生存因子的作用。最后,我们通过肱动脉血流介导的血管内皮舒张功能,检测了手术绝经对血管内皮功能的影响。手术绝经1周后血管内皮功能明显下降。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Rapid changes of flow-mediated dilatation after surgical menopause.
手术绝经后血流介导的扩张迅速变化。
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ohmichi M
  • 通讯作者:
    Ohmichi M
Cardiovascular effects of SERM
SERM 对心血管的影响
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ohmichi M.;et al.
  • 通讯作者:
    et al.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OHMICHI Masahide其他文献

OHMICHI Masahide的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OHMICHI Masahide', 18)}}的其他基金

To control in invasion and metastasis through EMT (Epithelial-Mesenchymal-Transition) functional analysis of CD24 in endometrial cancer
通过CD24的EMT(上皮-间质-转化)功能分析控制子宫内膜癌的侵袭和转移
  • 批准号:
    24390384
  • 财政年份:
    2012
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Developing of polymeric micelle for molecular targeting to cancer stem cells in ovarian cancer patients.
开发用于分子靶向卵巢癌患者癌症干细胞的聚合物胶束。
  • 批准号:
    22659303
  • 财政年份:
    2010
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Analysis of chemo-resistance genes with promoter micro-array in ovarian cancer
卵巢癌化疗耐药基因启动子微阵列分析
  • 批准号:
    18390448
  • 财政年份:
    2006
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The antiproliferative effect of GnRH agonists and the mechanism of the resistance to cisplatin in human ovarian cancer cell line
GnRH激动剂对人卵巢癌细胞增殖的抑制作用及顺铂耐药机制
  • 批准号:
    10557147
  • 财政年份:
    1998
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).

相似海外基金

How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures
双磷酸盐如何影响骨基质和重塑:对非典型股骨骨折的影响
  • 批准号:
    10586949
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau.
治疗由过度磷酸化 tau 引起的神经毒性和认知缺陷。
  • 批准号:
    10815399
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Improving bone mass and quality in comorbid diabetes and chronic kidney disease
改善糖尿病和慢性肾病共病患者的骨量和骨质量
  • 批准号:
    10590035
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
  • 批准号:
    10607151
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer
探索雌激素受体阴性乳腺癌免疫预防的新策略
  • 批准号:
    10583390
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Long-Term Approaches to Treating Osteoporosis
治疗骨质疏松症的长期方法
  • 批准号:
    10804038
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Irreversible Estrogen Receptor Inhibitors
不可逆雌激素受体抑制剂
  • 批准号:
    10507624
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Repurpose bone therapeutics for intervertebral disc degeneration in aged mice
重新利用骨疗法治疗老年小鼠椎间盘退变
  • 批准号:
    10445485
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Benefits and Harms of Long-term Osteoporosis Pharmacotherapy: Impact of Treatment Length, Type, Switching, and Holidays
长期骨质疏松症药物治疗的好处和坏处:治疗长度、类型、转换和假期的影响
  • 批准号:
    10515946
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Repurpose bone therapeutics for intervertebral disc degeneration in aged mice
重新利用骨疗法治疗老年小鼠椎间盘退变
  • 批准号:
    10709661
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了